A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del (VX18-445-109)
Details
- Therapeutic approach
- Restore CFTR Function
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT002046
- Last updated
- 08/11/2019
Full title
A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/ Tezacaftor / Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
Study detailsA Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
- Phase
- Phase 3b
- Recruitment target
- 158
- CF sponsor
- Vertex Pharmaceuticals Incorporated
- CF sponsor type
- Commercial
Who can take part?
- Age range
- 12 years and older
- Including people
12 Years and older
Homozygous for the F508del mutation
FEV1 value ≥40% and ≤90%- Excluding people
Clinically significant cirrhosis with or without portal hypertension.
Lung infection
Get in touch